Researchers analyzed 14 million doctors’ notes and 15 million clinical data entries from more than 135,000 patients with and without diabet...

Eli Lilly India chief Winselow Tucker said the company’s strategy of combining a strong product with ecosystem partnerships and patient edu...

At a recent industry summit, executives from Eli Lilly and Novo Nordisk unveiled their game plan for tackling weight-loss medications in In...

In an exciting collaboration, Cipla and Eli Lilly have unveiled Yurpeak, a groundbreaking diabetes and weight management medication, now av...

Semaglutide, the active ingredient in Novo's Wegovy and Ozempic, and tirzepatide, sold as Zepbound and Mounjaro by Lilly, are so effective ...

The World Health Organization has included Semaglutide and Tirzepatide, popular weight-loss drugs, in its Model List of Essential Medicines...

The Vishwa Swasthya Sangathan has included GLP-1 drugs for diabetes in its essential medicines list. This move aims to enhance global acces...

A recent analysis of U.S. pharmacy claims reveals that nearly two-thirds of patients who initiated Wegovy or Zepbound in early 2024 continu...

Eli Lilly's weight-loss and diabetes drug, Mounjaro, has rapidly gained popularity in India, achieving Rs 24 crore in sales within three mo...

Mounjaro, a newly launched weight-loss and diabetes drug, is now available in India. Developed by Eli Lilly, it promises more effectiveness...

The 2.5 mg vial and 5 mg vial will be available at Rs 3,500 and Rs 4,375, respectively. A spokesperson said as Mounjaro (tirzepatide) is a ...

The FDA approves Zepbound, originally used for type 2 diabetes and weight loss, for treating obstructive sleep apnea (OSA) in obese adults....

Eli Lilly’s Zepbound has outperformed Novo Nordisk’s Wegovy in a recent clinical trial, with patients losing more weight on average. While ...

U.S. health insurance claims analysis shows that two years after starting Novo Nordisk's Wegovy or similar GLP-1 drugs, annual medical cost...

Shares were off about 1% at $696.82 after gaining about 11% in January, making Lilly the eighth largest company in the U.S. by market capit...

SVB Securities believes that the new diabetes drug by Eli Lilly might be able to address patients' obesity and might lead to more significa...

"Treatment of obesity to achieve a sustained loss of 15 per cent body weight has been shown to have a major impact on type 2 diabetes progr...